Invention Grant
- Patent Title: Isoindolinone inhibitors of the MDM2-P53 interaction having anticancer activity
-
Application No.: US15763724Application Date: 2016-09-29
-
Publication No.: US10526311B2Publication Date: 2020-01-07
- Inventor: Gianni Chessari , Steven Howard , Ildiko Maria Buck , Benjamin David Cons , Christopher Norbert Johnson , Rhian Sara Holvey , David Charles Rees , Jeffrey David St. Denis , Emiliano Tamanini , Bernard Thomas Golding , Ian Robert Hardcastle , Celine Florence Cano , Duncan Charles Miller , Martin Edward Mäntylä Noble , Roger John Griffin , James Daniel Osborne , Joanne Peach , Arwel Lewis , Kim Louise Hirst , Benjamin Paul Whittaker , David Wyn Watson , Dale Robert Mitchell
- Applicant: ASTEX THERAPEUTICS LIMITED , CANCER RESEARCH TECHNOLOGY LIMITED
- Applicant Address: GB Cambridge GB London
- Assignee: ASTEX THERAPEUTICS LIMITED,CANCER RESEARCH TECHNOLOGY LIMITED
- Current Assignee: ASTEX THERAPEUTICS LIMITED,CANCER RESEARCH TECHNOLOGY LIMITED
- Current Assignee Address: GB Cambridge GB London
- Agency: Heslin Rothenberg Farley & Mesiti P.C.
- Priority: GB1517216.6 20150929
- International Application: PCT/GB2016/053041 WO 20160929
- International Announcement: WO2017/055859 WO 20170406
- Main IPC: C07D401/06
- IPC: C07D401/06 ; A61K31/4439 ; C07D401/14 ; C07D403/06 ; C07D407/14 ; C07D409/14 ; C07D417/14 ; A61P35/00 ; A61K31/444 ; A61K31/4545 ; A61K31/496 ; A61K31/501 ; A61K31/506 ; A61K31/5377 ; A61K45/06
Abstract:
The invention provides a compound of formula (I): or tautomer or a solvate or a pharmaceutically acceptable salt thereof, wherein the various substituents are as defined in the claims. Also provided are pharmaceutical compositions containing the compounds of formula (I), processes for making the compounds and the medical uses of the compounds.
Public/Granted literature
- US20190055215A1 ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY Public/Granted day:2019-02-21
Information query
